3rd Quarter 2025
Key topics in this quarter’s edition include:
- Wegovy (injectable) for treatment of metabolic dysfunction–associated steatohepatitis (MASH)
- Wegovy (oral) for chronic weight management
- Depemokimab for treatment of asthma and chronic rhinosinusitis
- Remibrutinib for treatment of chronic spontaneous urticaria